Proteona co-founder publishes novel AI method for single cell data annotation
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
SINGAPORE, 5 November 2019 - Dr Shawn Hoon, a scientific co-founder of Proteona, has published a novel AI method for single cell analysis data annotation. The article, titled “MapCell: Learning a comparative cell type distance metric with Siamese neural nets with applications towards cell-types identification across experimental datasets”, has been published on bioRxiv on 4 November 2019.
Read the full publication here.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.